On March 18, 2025, David Novack, President & Chief Operating Officer of Dynavax Technologies Corp, sold 14,020 shares of the company. Following this transaction, the insider now owns 8,078 shares of Dynavax Technologies Corp.
Dynavax Technologies Corp (DVAX, Financial) is a biopharmaceutical company that focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company develops and commercializes novel vaccines and immuno-oncology therapeutics.
The insider transaction history for Dynavax Technologies Corp indicates that there have been no insider buys over the past year. However, there have been three insider sells during the same period. Over the past year, David Novack has sold a total of 46,784 shares and has not purchased any shares.
As of the date of the recent transaction, shares of Dynavax Technologies Corp were trading at $13.58 each, giving the stock a market cap of $1.714 billion. The company's price-earnings ratio stands at 76.78, which is higher than the industry median of 20.56 and also higher than the company’s historical median price-earnings ratio.
With a trading price of $13.58 and a GF Value of $9.38, Dynavax Technologies Corp has a price-to-GF-Value ratio of 1.45, indicating that the stock is significantly overvalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
